X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CIPLA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CIPLA DISHMAN PHARMA/
CIPLA
 
P/E (TTM) x 25.1 43.9 57.1% View Chart
P/BV x 3.3 3.6 92.4% View Chart
Dividend Yield % 0.7 0.4 187.3%  

Financials

 DISHMAN PHARMA   CIPLA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CIPLA
Mar-17
DISHMAN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs374622 60.2%   
Low Rs129458 28.1%   
Sales per share (Unadj.) Rs197.8181.9 108.8%  
Earnings per share (Unadj.) Rs21.212.9 164.8%  
Cash flow per share (Unadj.) Rs34.729.3 118.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 214.6%  
Book value per share (Unadj.) Rs179.9155.7 115.5%  
Shares outstanding (eoy) m80.69804.51 10.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.0 42.8%   
Avg P/E ratio x11.942.0 28.3%  
P/CF ratio (eoy) x7.218.4 39.3%  
Price / Book Value ratio x1.43.5 40.3%  
Dividend payout %9.415.5 60.7%   
Avg Mkt Cap Rs m20,306434,516 4.7%   
No. of employees `0000.823.0 3.6%   
Total wages/salary Rs m5,35526,338 20.3%   
Avg. sales/employee Rs Th19,252.76,349.1 303.2%   
Avg. wages/employee Rs Th6,459.51,143.0 565.1%   
Avg. net profit/employee Rs Th2,064.1449.3 459.3%   
INCOME DATA
Net Sales Rs m15,961146,302 10.9%  
Other income Rs m2652,287 11.6%   
Total revenues Rs m16,226148,589 10.9%   
Gross profit Rs m4,10324,758 16.6%  
Depreciation Rs m1,09113,229 8.2%   
Interest Rs m9441,594 59.3%   
Profit before tax Rs m2,33412,222 19.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-70 -1.6%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,798 34.7%   
Profit after tax Rs m1,71110,354 16.5%  
Gross profit margin %25.716.9 151.9%  
Effective tax rate %26.714.7 181.7%   
Net profit margin %10.77.1 151.5%  
BALANCE SHEET DATA
Current assets Rs m11,01887,370 12.6%   
Current liabilities Rs m9,51733,081 28.8%   
Net working cap to sales %9.437.1 25.3%  
Current ratio x1.22.6 43.8%  
Inventory Days Days11087 127.1%  
Debtors Days Days3562 55.9%  
Net fixed assets Rs m16,304111,567 14.6%   
Share capital Rs m1611,609 10.0%   
"Free" reserves Rs m12,907123,645 10.4%   
Net worth Rs m14,516125,254 11.6%   
Long term debt Rs m4,18936,454 11.5%   
Total assets Rs m29,805209,532 14.2%  
Interest coverage x3.58.7 40.0%   
Debt to equity ratio x0.30.3 99.2%  
Sales to assets ratio x0.50.7 76.7%   
Return on assets %8.95.7 156.2%  
Return on equity %11.88.3 142.6%  
Return on capital %17.58.5 206.2%  
Exports to sales %24.834.2 72.5%   
Imports to sales %3.78.3 44.8%   
Exports (fob) Rs m3,95650,050 7.9%   
Imports (cif) Rs m59612,203 4.9%   
Fx inflow Rs m4,95251,066 9.7%   
Fx outflow Rs m69717,678 3.9%   
Net fx Rs m4,25533,388 12.7%   
CASH FLOW
From Operations Rs m2,78623,824 11.7%  
From Investments Rs m-1,529-13,127 11.6%  
From Financial Activity Rs m-941-13,239 7.1%  
Net Cashflow Rs m316-2,478 -12.8%  

Share Holding

Indian Promoters % 61.4 16.0 383.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 12.7 23.7 53.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 22.1 26.2 84.4%  
Shareholders   46,261 161,166 28.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Share Buybacks, GST Cess on Motor Vehicles, and Top Stocks in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Wednesday and finished their session in the green for the second straight session. Heavy buying was seen in realty stocks, metal stocks and bank stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SUVEN LIFE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS